PCa Commentary | Volume 152 – April 2021
This Commentary provides a primer on using genomic classifiers and genomic sequencing to guide management decisions for prostate cancer.
Read MoreSelect Page
Edward Weber, MD, is a retired medical oncologist living in Seattle, Washington. He was born and raised in a suburb of Reading, Pennsylvania. After graduating from Princeton University in 1956 with a BA in History, Dr. Weber attended medical school at the University of Pennsylvania. His internship training took place at the University of Vermont in Burlington.
A tour of service as a Naval Flight Surgeon positioned him on Whidbey Island, Washington, and this introduction to the Pacific Northwest ultimately proved irresistible. Following naval service, he received postgraduate training in internal medicine in Philadelphia at the Pennsylvania Hospital and then pursued a fellowship in hematology and oncology at the University of Washington.
His career in medical oncology was at the Tumor Institute of the Swedish Hospital in Seattle where his practice focused largely on the treatment of patients experiencing lung, breast, colon, and genitourinary cancer and malignant lymphoma.
Toward the end of his career, he developed a particular concentration on the treatment of prostate cancer. Since retirement in 2002, he has authored the PCa Commentary, published by the Prostate Cancer Treatment Research Foundation, an analysis of new developments in the prostate cancer field with essays discussing and evaluating treatment management options in this disease. He is a regular speaker at various prostate cancer support groups around Seattle.
Posted by Edward Weber, MD | Apr 2021
This Commentary provides a primer on using genomic classifiers and genomic sequencing to guide management decisions for prostate cancer.
Read MorePosted by Edward Weber, MD | Dec 2020
This Commentary discusses how olaparib and rucaparib offer a needed additional treatment option for men with mCRPC.
Read MorePosted by Edward Weber, MD | Oct 2020
This Commentary discusses how radium-223 therapy for mCRPC prolongs survival, improving with earlier use and when combined with other agents.
Read MorePosted by Edward Weber, MD | Sep 2020
PCa Commentary | Volume 145 – September 2020 Posted by Edward Weber | September 2020 PSA,...
Read MorePosted by Edward Weber, MD | Aug 2020
PCa Commentary | Volume 144 – August 2020 Posted by Edward Weber | August 2020 THE...
Read More